Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia

Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called intravenous lacosamide for treating sudden, severe pain caused by trigeminal neuralgia, a condition that affects the facial nerves. The trial is taking place at the Hospital de Bellvitge and is currently looking for participants. If you or someone you know has been diagnosed with trigeminal neuralgia and is experiencing a sudden flare-up of pain, you might be eligible to join the study. To qualify, participants need to be over 18 years old and must give their consent to take part in the trial.

If you decide to participate, you will receive intravenous lacosamide as part of your treatment plan in the emergency department. The goal of the study is to see how well this medication helps relieve your pain and to monitor any side effects. It’s important to note that individuals with certain medical conditions or those who have had specific allergic reactions to lacosamide will not be able to join the study. This trial aims to provide valuable information that could improve pain management for people with trigeminal neuralgia in the future.

Gender

ALL

Eligibility criteria

• • All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion.
• Inclusion Criteria:
• • Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3).
• • Age over 18 years.
• • Signed informed consent.
• Exclusion Criteria:
• • Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block).
• • Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent.
• • Language barrier.
• • Lack of cooperation.